Publications

Show Filters

Searches all publications.

Search Fulltext

Publications

Section

Select publication to see the relevant sections.

Publication Date

    E.g., 2018-06-21
    E.g., 2018-06-21

Articles

19304 items
3:50 PM, May 11, 2018  |  BioCentury | Finance

Watching the wave

After raising the largest ever series B round for a Chinese biotech, CStone Pharmaceuticals Co. Ltd. should have enough funding to run four pivotal cancer studies in parallel as it monitors the performance of the...
2:33 PM, May 11, 2018  |  BioCentury | Finance

Seroquel stepping stone

The $538 million acquisition by Luye Pharma Group Ltd. (HKSE:2186) of Seroquel quetiapine fumarate from AstraZeneca plc (LSE:AZN; NYSE:AZN) will lay the commercial groundwork in new emerging markets for the Chinese pharma’s internal CNS pipeline. On...
1:39 PM, May 11, 2018  |  BioCentury | Emerging Company Profile

Enterin the gut

Enterin Inc. has a new twist on the longstanding Parkinson’s disease target alpha synuclein. The biotech is inhibiting the protein’s accumulation in intestinal nerves rather than in the brain, with the goal of treating constipation...
12:19 PM, May 11, 2018  |  BioCentury | Finance

Earnings on deck

Earnings on deck At least four profitable pharmas are slated to report earnings this week. (A) 12-month EPS; Source: Yahoo! Finance, Financial Times, company websites CompanyDatePre/post mkt1Q18 EPS est1Q17 EPSExpected chgTakeda Pharmaceutical Co. Ltd. (Tokyo:4502)5/14PostNA¥146.26 (A)NAEisai Co....
7:59 PM, May 04, 2018  |  BioCentury | Strategy

Thinking globally, acting locally

BeiGene Ltd.’s hire of Pfizer Inc. veteran Xiaobing Wu is one of the loudest signals to date that regulatory and reimbursement reforms have made it attractive to develop and commercialize innovative drugs in China. Wu’s...
6:46 PM, May 04, 2018  |  BioCentury | Product Development

Rebuilding Biogen’s brain

Biogen Inc. is still a long way from a full rebuild of its pipeline, with an Alzheimer’s disease-laden Phase III lineup that needs to diversify. But there’s progress in the early- to mid-stage programs where...
5:12 PM, May 04, 2018  |  BioCentury | Finance

Splitting Ironwood

Ironwood Pharmaceuticals Inc. has accomplished what many biotechs aspire to but few achieve. It has built a high-growth GI business on the cusp of profitability, and discovered and developed a well-stocked pipeline of clinical candidates...
5:06 PM, May 04, 2018  |  BioCentury | Finance

Earnings on deck

Earnings on deck At least 11 profitable biotechs and pharmas are slated to report earnings this week. (A) Fiscal 3Q; (B) 12-month EPS; Source: Yahoo! Finance, Financial Times, company websites CompanyDatePre/post mkt1Q18 EPS est1Q17 EPSExpected chgMyriad Genetics...
3:26 PM, May 04, 2018  |  BioCentury | Finance

Voucher equilibrium

At $110 million, the sticker price on a Priority Review voucher from Spark Therapeutics Inc. (NASDAQ:ONCE) appears to be the new normal. Jazz Pharmaceuticals plc (NASDAQ:JAZZ) purchased the voucher on April 30; Spark received it in...
10:57 AM, May 04, 2018  |  BioCentury | Politics, Policy & Law

A Remembrance: An exceptional responder

Jane Reese-Coulbourne was an exceptional responder. In 1990, faced with a diagnosis of advanced breast cancer, she enrolled in a clinical trial at the National Cancer Institute, enduring a grueling regimen of high doses of...

Pages